Skip to main content

Advertisement

SpringerLink
Log in

Metabolic syndrome and its relationship with the achievement of minimal disease activity state in psoriatic arthritis patients: an observational study

  • DIAGNOSTICS AND ENVIRONMENTAL FACTORS
  • Published:
Immunologic Research Aims and scope Submit manuscript

Abstract

The aim of the study was to evaluate the influence of metabolic syndrome (MetS) on achieving minimal disease activity (MDA) in psoriatic arthritis (PsA) patients treated with anti-tumor necrosis factor (TNF)-α with a follow-up period of 24 months. A cohort of PsA patients was assessed at the University Federico II of Naples and at University of Padova. For the aim of the present study, patients’ data were collected at baseline (T0), at 12 months (T1) and at 24 months (T2). Assessment of metabolic and disease activity parameters was performed at each visit. The NCEP-ACT III criteria were used to identify subjects with MetS and the MDA criteria to evaluate the disease activity. On the basis of the exclusion and inclusion criteria, 330 subjects were included in the study; 134 patients (40.7 %) were classified as not having MetS and 196 (59.3 %) as having MetS. An inverse association was found between presence of metabolic syndrome and the probability of achieving MDA. Univariate analysis indicated that patients with metabolic syndrome were less likely to achieve MDA than patients without metabolic syndrome (OR 0.45, p < 0.001). This inverse association remained statistically significant in the multivariate regression model (OR 0.56, p < 0.001). Metabolic syndrome is associated with a lower probability of achieving MDA in PsA patients in therapy with anti-TNF-α.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Moll JM, Wright V. Psoriatic arthritis. Semin Arthritis Rheum. 1973;3:55–78.

    Article  CAS  PubMed  Google Scholar 

  2. Raychaudhuri SK, Maverakis E, Raychaudhuri SP. Diagnosis and classification of psoriasis. Autoimmun Rev. 2014;13:490–5.

    Article  PubMed  Google Scholar 

  3. Soscia E, Sirignano C, Catalano O, Atteno M, Costa L, Caso F, Peluso R, Bruner V, Aquino MM, Del Puente A, Salvatore M, Scarpa R. New developments in magnetic resonance imaging of the nail unit. J Rheumatol Suppl. 2012;89:49–53.

    Article  PubMed  Google Scholar 

  4. Taylor W, Gladman D, Helliwell P, Marchesoni A, Mease P, Mielants H. Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum. 2006;54:2665–73.

    Article  PubMed  Google Scholar 

  5. Tillett W, Costa L, Jadon D, Wallis D, Cavill C, McHugh J, Korendowych E, McHugh N. The classification for psoriatic arthritis (CASPAR) criteria—a retrospective feasibility, sensitivity, and specificity study. J Rheumatol. 2012;39:154–6.

    Article  PubMed  Google Scholar 

  6. Chimenti MS, Ballanti E, Perricone C, Cipriani P, Giacomelli R, Perricone R. Immunomodulation in psoriatic arthritis: focus on cellular and molecular pathways. Autoimmun Rev. 2013;12:599–606.

    Article  CAS  PubMed  Google Scholar 

  7. Fiocco U, Accordi B, Martini V, Oliviero F, Facco M, Cabrelle A, Piva L, Molena B, Caso F, Costa L, Scanu A, Pagnin E, Atteno M, Scarpa R, Basso G, Semenzato G, Punzi L, Doria A, Dayer JM. JAK/STAT/PKCδ molecular pathways in synovial fluid T lymphocytes reflect the in vivo T helper-17 expansion in psoriatic arthritis. Immunol Res. 2014;58:61–9.

    Article  CAS  PubMed  Google Scholar 

  8. Suzuki E, Mellins ED, Gershwin ME, Nestle FO, Adamopoulos IE. The IL-23/IL-17 axis in psoriatic arthritis. Autoimmun Rev. 2014;13:496–502.

    Article  CAS  PubMed  Google Scholar 

  9. Ballanti E, Perricone C, di Muzio G, Kroegler B, Chimenti MS, Graceffa D, Perricone R. Role of the complement system in rheumatoid arthritis and psoriatic arthritis: relationship with anti-TNF inhibitors. Autoimmun Rev. 2011;10:617–23.

    Article  CAS  PubMed  Google Scholar 

  10. Scarpa R, Costa L, Atteno M, Del Puente A, Caso F, Moll JM. Psoriatic arthritis: advances in pharmacotherapy based on molecular target. Expert Opin Pharmacother. 2013;14:2311–3.

    Article  CAS  PubMed  Google Scholar 

  11. Novelli L, Chimenti MS, Chiricozzi A, Perricone R. The new era for the treatment of psoriasis and psoriatic arthritis: perspectives and validated strategies. Autoimmun Rev. 2014;13:64–9.

    Article  CAS  PubMed  Google Scholar 

  12. Fiorino G, Girolomoni G, Lapadula G, Orlando A, Danese S, Olivieri I. SIR, SIDeMaST, and IG-IBD. The use of biosimilars in immune-mediated disease: a joint Italian society of rheumatology (SIR), Italian society of dermatology (SIDeMaST), and Italian group of inflammatory bowel disease (IG-IBD) position paper. Autoimmun Rev. 2014;13:751–5.

    Article  PubMed  Google Scholar 

  13. Fiocco U, Sfriso P, Oliviero F, Lunardi F, Calabrese F, Scagliori E, Cozzi L, Di Maggio A, Nardacchione R, Molena B, Felicetti M, Gazzola K, Stramare R, Rubaltelli L, Accordi B, Costa L, Roux-Lombard P, Punzi L, Dayer JM. Blockade of intra-articular TNF in peripheral spondyloarthritis: its relevance to clinical scores, quantitative imaging and synovial fluid and synovial tissue biomarkers. Jt Bone Spine. 2013;80:165–70.

    Article  CAS  Google Scholar 

  14. Scarpa R, Atteno M, Lubrano E, Provenzano G, D’Angelo S, Spadaro A, Costa L, Olivieri I. The effectiveness and safety of TNF-alpha blockers in the treatment of early psoriatic arthritis: an Italian multicentre longitudinal observational pilot study. Clin Rheumatol. 2011;30:1063–7.

    Article  PubMed Central  PubMed  Google Scholar 

  15. Chimenti MS, Graceffa D, Perricone R. Anti-TNFα discontinuation in rheumatoid and psoriatic arthritis: is it possible after disease remission? Autoimmun Rev. 2011;10:636–40.

    Article  CAS  PubMed  Google Scholar 

  16. Atteno M, Costa L, Matarese A, Caso F, Del Puente A, Cantarini L, Bocchino ML, Sanduzzi A, Scarpa R. The use of TNF-α blockers in psoriatic arthritis patients with latent tuberculosis infection. Clin Rheumatol. 2014;33:543–7.

    Article  PubMed Central  PubMed  Google Scholar 

  17. Costa L, Caso F, Atteno M, Giannitti C, Spadaro A, Ramonda R, Vezzù M, Del Puente A, Morisco F, Fiocco U, Galeazzi M, Punzi L, Scarpa R. Long-term safety of anti-TNF-α in PsA patients with concomitant HCV infection: a retrospective observational multicenter study on 15 patients. Clin Rheumatol. 2014;33:273–6.

    Article  PubMed  Google Scholar 

  18. Sanduzzi A, Bocchino M, Atteno M, Costa L, Ponticiello A, Matarese A, Spanò A, Bruner V, Peluso R, Aquino MM, Del Puente A, Scarpa R. Screening and monitoring of latent tubercular infection in patients taking tumor necrosis factor-α blockers for psoriatic arthritis. J Rheumatol Suppl. 2012;89:82–5.

    Article  PubMed  Google Scholar 

  19. Fiorino G, Danese S, Pariente B, Allez M. Paradoxical immune-mediated inflammation in inflammatory bowel disease patients receiving anti-TNF-α agents. Autoimmun Rev. 2014;13:15–9.

    Article  CAS  PubMed  Google Scholar 

  20. Piga M, Chessa E, Ibba V, Mura V, Floris A, Cauli A, Mathieu A. Biologics-induced autoimmune renal disorders in chronic inflammatory rheumatic diseases: systematic literature review and analysis of a monocentric cohort. Autoimmun Rev. 2014;13:873–9.

    Article  CAS  PubMed  Google Scholar 

  21. Selmi C. Diagnosis and classification of autoimmune uveitis. Autoimmun Rev. 2014;13:591–4.

    Article  CAS  PubMed  Google Scholar 

  22. Scarpa R, Ayala F, Caporaso N, Olivieri I. Psoriasis, psoriatic arthritis, or psoriatic disease? J Rheumatol. 2006;33:210–2.

    PubMed  Google Scholar 

  23. Ritchlin CT. From skin to bone: translational perspectives on psoriatic disease. J Rheumatol. 2008;35:1434–7.

    PubMed  Google Scholar 

  24. Boehncke WH, Boehncke S. Cardiovascular mortality in psoriasis and psoriatic arthritis: epidemiology, pathomechanisms, therapeutic implications, and perspectives. Curr Rheumatol Rep. 2012;14:343–8.

    Article  PubMed  Google Scholar 

  25. Ramonda R, Lo Nigro A, Modesti V, Nalotto L, Musacchio E, Iaccarino L, Punzi L, Doria A. Atherosclerosis in psoriatic arthritis. Autoimmun Rev. 2011;10:773–8.

    Article  CAS  PubMed  Google Scholar 

  26. Sarzi-Puttini P, Atzeni F, Gerli R, Bartoloni E, Doria A, Barskova T, Matucci-Cerinic M, Sitia S, Tomasoni L, Turiel M. Cardiac involvement in systemic rheumatic diseases: an update. Autoimmun Rev. 2010;9:849–52.

    Article  PubMed  Google Scholar 

  27. Ramonda R, Puato M, Punzi L, Rattazzi M, Zanon M, Balbi G, Ortolan A, Frallonardo P, Faggin E, Plebani M, Zaninotto M, Lorenzin M, Pauletto P, Doria A. Atherosclerosis progression in psoriatic arthritis patients despite the treatment with tumor necrosis factor-alpha blockers: a two-year prospective observational study. Jt Bone Spine. 2014;. doi:10.1016/j.jbspin.2014.02.005.

    Google Scholar 

  28. Costa L, Caso F, D’Elia L, Atteno M, Peluso R, Del Puente A, Strazzullo P, Scarpa R. Psoriatic arthritis is associated with increased arterial stiffness in the absence of known cardiovascular risk factors: a case control study. Clin Rheumatol. 2012;31:711–5.

    Article  PubMed  Google Scholar 

  29. Mok CC, Ko GT, Ho LY, Yu KL, Chan PT, To CH. Prevalence of atherosclerotic risk factors and the metabolic syndrome in patients with chronic inflammatory arthritis. Arthritis Care Res (Hoboken). 2011;63:195–202.

    Article  Google Scholar 

  30. Raychaudhuri SK, Chatterjee S, Nguyen C, Kaur M, Jialal I, Raychaudhuri SP. Increased prevalence of the metabolic syndrome in patients with psoriatic arthritis. Metab Syndr Relat Disord. 2010;8:331–4.

    Article  PubMed Central  PubMed  Google Scholar 

  31. Pereira RM, de Carvalho JF, Bonfá E. Metabolic syndrome in rheumatological diseases. Autoimmun Rev. 2009;8:415–9.

    Article  CAS  PubMed  Google Scholar 

  32. Raychaudhuri SP. Comorbidities of psoriatic arthritis—metabolic syndrome and prevention: a report from the GRAPPA 2010 annual meeting. J Rheumatol. 2012;39:437–40.

    Article  PubMed  Google Scholar 

  33. Eder L, Jayakar J, Pollock R, Pellett F, Thavaneswaran A, Chandran V, Rosen CF, Gladman DD. Serum adipokines in patients with psoriatic arthritis and psoriasis alone and their correlation with disease activity. Ann Rheum Dis. 2012. doi:10.1136/annrheumdis-2012-202325.

    Google Scholar 

  34. Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet. 2005;365:1415–28.

    Article  CAS  PubMed  Google Scholar 

  35. Tam LS, Tomlinson B, Chu TT, Li M, Leung YY, Kwok LW, et al. Cardiovascular risk profile of patients with psoriatic arthritis compared to controls—The role of inflammation. Rheumatology. 2008;47:718–23.

    Article  PubMed  Google Scholar 

  36. Jones SM, Harris CP, Lloyd J, Stirling CA, Reckless JP, McHugh NJ. Lipoproteins and their subfractions in psoriatic arthritis: identification of an atherogenic profile with active joint disease. Ann Rheum Dis. 2000;59:904–9.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  37. Costa L, Caso F, Atteno M, Del Puente A, Darda MA, Caso P, Ortolan A, Fiocco U, Ramonda R, Punzi L, Scarpa R. Impact of 24-month treatment with etanercept, adalimumab, or methotrexate on metabolic syndrome components in a cohort of 210 psoriatic arthritis patients. Clin Rheumatol. 2014;33:833–9.

    PubMed  Google Scholar 

  38. Suryaprasad AG, Prindiville T. The biology of TNF blockade. Autoimmun Rev. 2003;2:346–57.

    Article  CAS  PubMed  Google Scholar 

  39. Hotamisligil GS. Inflammation and metabolic disorders. Nature. 2006;444:860–7.

    Article  CAS  PubMed  Google Scholar 

  40. Executive Summary of The Third Report of The. National cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults. JAMA. 2001;285:2486–97.

    Article  Google Scholar 

  41. Coates LC, Fransen J, Helliwell PS. Defining minimal disease activity in psoriatic arthritis: a proposed objective target for treatment. Ann Rheum Dis. 2010;69:48–53.

    Article  CAS  PubMed  Google Scholar 

  42. Coates LC, Helliwell PS. Validation of minimal disease activity criteria for psoriatic arthritis using interventional trial data. Arthritis Care Res (Hoboken). 2010;62:965–9.

    Article  Google Scholar 

  43. Haroon M, Gallagher P, Heffernan E, FitzGerald O. High prevalence of metabolic syndrome and of insulin resistance in psoriatic arthritis is associated with the severity of underlying disease. J Rheumatol. 2014;41:1357–65.

    Article  PubMed  Google Scholar 

  44. Eder L, Thavaneswaran A, Chandran V, Cook RJ, Gladman DD. Obesity is associated with a lower probability of achieving sustained minimal disease activity state among patients with psoriatic arthritis. Ann Rheum Dis. 2014. doi:10.1136/annrheumdis-2013-204448.

    Google Scholar 

  45. di Minno MN, Peluso R, Iervolino S, Lupoli R, Russolillo A, Scarpa R, di Minno G. Obesity and the prediction of minimal disease activity: a prospective study in psoriatic arthritis. Arthritis Care Res (Hoboken). 2013;65:141–7.

    Article  Google Scholar 

  46. Choi KM, Ryu OH, Lee KW, et al. Serum adiponectin, interleukin-10 levels and inflammatory markers in the metabolic syndrome. Diabetes Res Clin Pract. 2007;75:235–40.

    Article  CAS  PubMed  Google Scholar 

  47. Trayhurn P, Wood IS. Adipokines: inflammation and the pleiotropic role of white adipose tissue. Br J Nutr. 2004;92:347–55.

    Article  CAS  PubMed  Google Scholar 

  48. Sethi JK, Hotamisligil GS. The role of TNF alpha in adipocyte metabolism. Semin Cell Dev Biol. 1999;10:19–29.

    Article  CAS  PubMed  Google Scholar 

  49. Gremese E, Ferraccioli G. The metabolic syndrome: the crossroads between rheumatoid arthritis and cardiovascular risk. Autoimmun Rev. 2011;10:582–9.

    Article  CAS  PubMed  Google Scholar 

  50. Fonseca JE, Santos MJ, Canhão H, Choy E. Interleukin-6 as a key player in systemic inflammation and joint destruction. Autoimmun Rev. 2009;8:538–42.

    Article  CAS  PubMed  Google Scholar 

  51. Scrivo R, Vasile M, Bartosiewicz I, Valesini G. Inflammation as “common soil” of the multifactorial diseases. Autoimmun Rev. 2011;10:369–74.

    Article  PubMed  Google Scholar 

  52. Mease PJ. Tumour necrosis factor (TNF) in psoriatic arthritis: pathophysiology and treatment with TNF inhibitors. Ann Rheum Dis. 2002;61:298–304.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  53. Abou-Raya A, Abou-Raya S. Inflammation: a pivotal link between autoimmune diseases and atherosclerosis. Autoimmun Rev. 2006;5:331–7.

    Article  CAS  PubMed  Google Scholar 

Download references

Conflict of interest

The authors declare no conflicts of interest.

Author information

Authors and Affiliations

  1. Rheumatology Unit, Department of Clinical Medicine and Surgery, University Federico II, via S. Pansini 5, 80131, Naples, Italy

    Luisa Costa, Antonio Del Puente & Raffaele Scarpa

  2. Rheumatology Unit, Department of Medicine DIMED, University of Padova, Via Giustiniani 2, 35128, Padua, Italy

    Luisa Costa, Francesco Caso, Roberta Ramonda, Mariagrazia Lorenzin, Ugo Fiocco & Leonardo Punzi

  3. Interdepartmental Research Center of Systemic Autoimmune and Autoinflammatory Diseases, Rheumatology Unit, Policlinico Le Scotte, University of Siena, Viale Bracci 1, 53100, Siena, Italy

    Francesco Caso & Luca Cantarini

  4. Department of Statistics, Natural Science Academic Group, National University, Gazipur, 1704, Bangladesh

    Md Abud Darda

  5. Emergency Department Stroke Unit, Department of Neurology and Psychiatry, Policlinico Umberto I Hospital, Sapienza University of Rome, Viale del Policlinico 155, 00161, Rome, Italy

    Paolo Caso

Authors
  1. Luisa Costa
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Francesco Caso
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Roberta Ramonda
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Antonio Del Puente
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Luca Cantarini
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Md Abud Darda
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Paolo Caso
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Mariagrazia Lorenzin
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Ugo Fiocco
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Leonardo Punzi
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Raffaele Scarpa
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Luisa Costa.

Additional information

Luisa Costa and Francesco Caso have contributed equally to this study.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Costa, L., Caso, F., Ramonda, R. et al. Metabolic syndrome and its relationship with the achievement of minimal disease activity state in psoriatic arthritis patients: an observational study. Immunol Res 61, 147–153 (2015). https://doi.org/10.1007/s12026-014-8595-z

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12026-014-8595-z

Keywords

Search

Navigation